Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Spiriva Respimat tiotropium: Phase III data

The company initiated the TIOSPIR trial to compare Spiriva Respimat to Spiriva HandiHaler to further evaluate a non-significant numerical imbalance of mortality identified in an analysis of 5 clinical trials with Spiriva Respimat. In 2011, researchers at Johns Hopkins

Read the full 396 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers